Aeon Biopharma Inc (AEON) Institutional Ownership & 13F Filings (Q2 2026)

AEON ranks #8090 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

AEON is a top-conviction position for Dauntless Investment Group, LLC — at 7.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Wolff Wiese Magana LLC has trimmed its AEON position for two straight quarters, cutting it by $388.0 while still holding $171.0.

AEON is up 3.3% today, and institutions have been net buyers of $7.2M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AEON reported a net loss of $39.2M in its latest fiscal year.

• Not yet profitable — net loss of $39.2M in the latest fiscal year
• Net income declined year over year, from $42.0M to -$39.2M
• Operating cash flow was negative, using $17.3M in cash
• Current ratio of 0.49x — below the conventional 1.5x liquidity buffer